H. Lundbeck A/S
HLUN-A
Classificação em ações
#2963
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Preço da ação
$7.45
Valor de mercado
$6.23B
Variação (1 dia)
0.64%
Variação (1 ano)
35.57%
País
DK
Negociar H. Lundbeck A/S (HLUN-A)
Categoria
Healthcare
Rácio P/S de H. Lundbeck A/S (HLUN-A)
Rácio P/S em October 2026 TTM: 1.47
De acordo com os relatórios financeiros mais recentes e o preço das ações da H. Lundbeck A/S, o rácio P/S atual (TTM) é 1.47. No final de 2024, o rácio P/S era 1.86.
Histórico do rácio P/S da H. Lundbeck A/S de 2004 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 1.47 | -16.54% |
| 2025 | 1.76 | -5.55% |
| 2024 | 1.86 | 14.05% |
| 2023 | 1.63 | 15.17% |
| 2022 | 1.42 | -10.54% |
| 2021 | 1.58 | 333.52% |
| 2020 | 0.37 | -1.75% |
| 2019 | 0.37 | 2.99% |
| 2018 | 0.36 | -3.03% |
| 2017 | 0.37 | -9.12% |
| 2016 | 0.41 | -6.31% |
| 2015 | 0.44 | -7.62% |
| 2014 | 0.47 | 13.36% |
| 2013 | 0.42 | -2.97% |
| 2012 | 0.43 | 8.14% |
| 2011 | 0.40 | -7.76% |
| 2010 | 0.43 | -6.90% |
| 2009 | 0.46 | -18.23% |
| 2008 | 0.57 | -6.50% |
| 2007 | 0.61 | -18.48% |
| 2006 | 0.74 | -7.54% |
| 2005 | 0.80 | 4.96% |
| 2004 | 0.77 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.31 | 601.95% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 929.53% |
US
|
